Crossject SA

Paris Stock Exchange ALCJ.PA

Crossject SA Return on Assets (ROA) for the year ending December 31, 2023: -30.16%

Crossject SA Return on Assets (ROA) is -30.16% for the year ending December 31, 2023, a 11.17% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Crossject SA Return on Assets (ROA) for the year ending December 31, 2022 was -33.95%, a 0.95% change year over year.
Crossject SA Return on Assets (ROA) for the year ending December 31, 2021 was -34.28%, a -16.96% change year over year.
Crossject SA Return on Assets (ROA) for the year ending December 31, 2020 was -29.31%, a -0.07% change year over year.
Crossject SA Return on Assets (ROA) for the year ending December 31, 2019 was -29.29%, a 44.88% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Paris Stock Exchange: ALCJ.PA

Crossject SA

CEO	Mr. Patrick Alexandre
IPO Date	Feb. 20, 2014
Location	France
Headquarters	6 Rue Pauline Kergomard
Employees	105
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key trends

Past 5 years